ExploreWatchlistsPricing
  1. JP-listed companies
  2. Nano Holdings, Inc.
  3. Financials
  4. Operating margin (%)

Nano Holdings, Inc. (4571)

Market cap
¥10.6B
P/E ratio
-10.2x
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating margin (%) YoY (%)
Mar 31, 2025-696.1+9.12%
Mar 31, 2024-637.9+3.51%
Mar 31, 2023-616.3-21.06%
Mar 31, 2022-780.6+87.69%
Mar 31, 2021-415.9+107.98%
Mar 31, 2020-200-44.89%
Mar 31, 2019-362.8-82.43%
Mar 31, 2018-2,065.4+66.54%
Mar 31, 2017-1,240.2+44.91%
Mar 31, 2016-855.9+421.91%
Mar 31, 2015-164

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat